NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) revealed topline data from its Phase 3 BROADWAY clinical trial evaluating ...

NewAmsterdam Pharma Company N.V. (NAMS), a late-stage, clinical biopharmaceutical company, Tuesday announced positive topline data ...

After NewAmsterdam Pharma (NAMS) announced “positive” topline data from the company’s Phase 3 BROADWAY trial evaluating obicetrapib in adult ...

High bad cholesterol is a risk factor for a common type of heart disease, yet approximately 40% of Americans living with high cholesterol don't know they have it and don't treat it1,2. Watch our Local ...

Heterozygous familial hypercholesterolemia was associated with increased type 2 diabetes risk, especially among those with obesity and statin use.

The findings add to evidence that the company’s drug, obicetrapib, could change the narrative surrounding a once-abandoned ...

High bad cholesterol is a risk factor for a common type of heart disease, yet approximately 40% of Americans living with high ...

Discover the latest on Rhythm Pharmaceuticals, Inc. and its asset, imcivree, targeting rare obesity disorders and potential ...

HRCI ®, the premier credentialing and learning community for the human resource profession, today announced the expansion of ...

MetLife Investment Management LLC grew its holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) by 47.1% in ...

A new study reveals how genetic deficits, particularly in the Tbx1 gene, are linked to reduced brain volume and altered social behavior, findings relevant to autism and schizophrenia.

NewAmsterdam Pharma (Nasdaq: NAMS) took a commanding leap in the stock market, thanks to the announcement of positive topline data from its Phase 3 BROADWAY clinical trial. This trial evaluated ...